Digital therapeutics are clinically validated solutions that are delivered as applications, software and online programs, demonstrating the capability to facilitate positive outcomes when employed in the management of clinical conditions. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications. The primary benefits of digital therapeutics include reduction of treatment related costs, generation and maintenance of personalized health data, reduction in stress amongst healthcare professionals, and increase in the adherence to prescribed treatment regimens. In addition, these digital health solutions provide motivational support and inculcate healthy lifestyle changes in the target patient population. Currently, a wide variety of digital health applications and intuitive software are available for the aforementioned purposes. In fact, the COVID-19 pandemic has created a significant demand for remote healthcare solutions. Amidst other alternatives, digital therapeutics have emerged as a promising option since these can be employed as preventive or curative digital solutions for managing diverse target indications. A recent survey highlighted that the percentage of patients adopting digital therapeutics in the US rose from 4.7% to 18%, post the pandemic outbreak, resulting in an increased prescription rate of such therapeutics. Presently, there are more than 40 USFDA approved digital therapeutic solutions available in the market, including apps, software and devices, for the management of numerous therapeutic areas, such as mental health disorders, substance use disorders and reproductive health. It is worth noting that reSET, developed by Pear Therapeutics, was the first prescription digital therapeutics that received the USFDA approval in 2017. The application can be used as a method of opioid replacement therapy, increasing a patient's abstinence from substances of abuse during the treatment and enhancing the outpatient treatment program retention.
Owing to the increased adoption rate of digital solutions and rise in the demand for remote healthcare services, the companies involved in the digital therapeutics domain have witnessed a surge in the investment activity, with capital investments worth more than USD 9 billion. According to the recent trends, various digital therapeutic companies are engaged in providing personalized solutions, along with remote access to medical care facilities, including a health coach. Further, taking into consideration both the historical and contemporary scenarios, we believe that the digital therapeutics market presents lucrative investment opportunities for both short and long-term investors.
Scope of the Report
The Investor Series: Opportunities in the Digital Therapeutics Market (Focus on Need for Digital Therapeutics, Market Landscape of Innovators, Analysis of Product Offerings and Affiliated Value Propositions, Insights from Historical Funding Activity, Company Health Indexing, Financial Analysis of Key Public Ventures, Market Forecast and Opportunity Analysis, Insights from Publicly Disclosed Investor Exits and Key Acquisition Targets) report provides detailed information on the digital therapeutics market, covering the core and peripheral digital therapeutics solutions. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and an MS PowerPoint deck, which summarizes the key takeaways from the project, and insights drawn from the curated data. The report features the following details:
- A qualitative and quantitative (wherever information was available) perspective on the current need for digital therapeutics, highlighting some of the key applications of such offerings. Further, it highlights various challenges faced during stages of drug discovery, and the opinions of representatives from key stakeholder companies involved in this domain.
- A detailed analysis of digital therapeutics focused companies that were established post 2005, featuring inputs on observed trends related to basic input parameters, such as year of establishment, location of headquarters, company size, and type of venture.
- A quantitative perspective on the relative health (based on basic company details, product details, financing activity, and estimated revenues and profits) of the different innovator companies that have been described in detail in this report. This analysis is based on a proprietary scoring criterion, informed via secondary research.
- An assessment of the various solutions, offered by the companies mentioned above, featuring analysis based on number and types of products, and an informed perspective on the value of the offerings based on multiple relevant aspects, namely outreach-related value offered, developer-related value, value to patients and product-related value.
- A company competitiveness analysis, which offers a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in providing digital therapeutic solutions, captured in this report. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analyses.
- A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies discussed in the report. Further, it features a list of the leading investors in digital therapeutics, based on their participation in financing activity in this industry segment.
- An elaborate review of the overall digital therapeutics market from a financial perspective, including detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of the publicly listed companies within the market landscape dataset.
- A business risk analysis, based on some of the major categories of risk that are usually discussed in the industry, namely operations-related risks, overall business-related risks, financial risks, product / technology associated risks, and social, economic, environmental and political risks.
- Case studies of instances where investors have exited various digital therapeutics related ventures, offering insights on return on investments made (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the digital therapeutics market.
- A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures around which there is likely to be interest for future acquisitions / mergers.
One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated within the digital therapeutics market, over the coming decades. We have provided informed estimates on the likely evolution of the market, during the period 2023-2035, based on various parameters, such as historical sales, target patient population, likely adoption rates and expected pricing. Our year wise projections of the current and forecasted opportunity within the digital therapeutics market have been further segmented across type of solution (standalone software application, combination offerings of software application + device, combination offerings of software application + AI support , combination offerings of software application + personal coach, combination offerings of software application + device + AI support , combination offerings of software application + device + personal coach and others), type of therapy (curative solutions and preventive solutions), therapeutic area (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders and others), and geographical regions (North America, Europe and Asia-Pacific and Rest of the World). In order to account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
EXCEL DELIVERABLE
Spreadsheet I includes details on the companies captured in the report, along with their respective products. It also features proprietary company health indexing analysis, value proposition analysis, insights from a detailed company competitiveness analysis and a list of industry stakeholders that were deemed to be likely targets for mergers / acquisitions, in the near future. The deliverable includes a summary dashboard, featuring interactive graphical representations of key insights generated from the data collated.
Spreadsheet II features a summary dashboard, including interactive graphical representations of some of the key insights generated related to the capital investments made in digital therapeutics domain (since 2011).
Spreadsheet III is a collection of multiple MS Excel sheets that provide summaries of insights generated from a detailed fundamental and technical financial analysis, of publicly listed ventures in the innovator companies’ dataset.
Spreadsheet IV offers our independent perspective on the various types of risks (namely operations-related risks, business-related risks, financial / asset-related risks, product / technology risks, and other risks) that the publicly listed ventures are presently exposed to; it includes a summary heat map representation that provides a pictorial perspective of the diversity and level of risks (as per our opinion), as well.
Spreadsheet V is a summary MS Excel dashboard, offering detailed graphical representations of the contemporary and future opportunity associated with the digital therapeutics domain.
Spreadsheet VI includes publicly available information on the investments made by selected investors in companies that are now publicly listed. Based on the data, we have offered a perspective on likely return on investments received by the mentioned investors.
POWERPOINT DELIVERABLE
Chapter 1 provides a brief summary of the content presented in the report, beginning with the need for digital therapeutics. It goes on to discuss some of the key benefits of these solutions and their advantages over the conventional therapies. Finally, the chapter provides an overview of the current scenario, offering a perspective on how, in light of recent funding activity, the market is likely to evolve over the coming years.
Chapter 2 and 3 feature brief (pictorial) summaries of the key objectives and approach used for data collection and analysis, in this study.
Chapter 4 features an executive summary of the key insights generated from the data and analytical outputs presented in the report.
Section I: Need for Digital Therapeutics and Innovators Landscape
Chapter 5 describes the current need for digital therapeutics, highlighting the key facts about the origin and development of digital therapeutics. It features information on the current areas of innovation, along with opinions of experts, describing various benefits of these therapies, and anticipated future challenges. It includes information on some of the key players that are engaged in this domain. The views presented in this chapter are backed by inputs from representatives from key stakeholder companies in this domain (as stated in publicly available articles and interview transcripts).
Chapter 6 focuses on some of the innovators (companies established on or after 2005) and features detailed analysis of the companies. It highlights important company related details, such as year of establishment, headquarters, company size, and type of venture.
Chapter 7 includes information on the various products and affiliated services offered by the companies captured in the report (listed in Chapter 6). It also features analysis based on number and types of products. Based on the insights and details presented in Chapter 6, we have developed a quantitative perspective on the relative health (based on basic company details, product details and financing activity) of the different innovator companies.
Chapter 8 offers an informed perspective on the apparent value proposition of the companies captured in the report (listed in Chapter 6). Based on multiple relevant inputs (as inferred from publicly disclosed value statements), namely outreach-related value offered, developer-related value, value to patients and product-related value, we developed an empirical framework to quantify the value proposition of a business.
Chapter 9 features a detailed company competitiveness analysis, offering a quantitative basis for comparing the developer of digital therapeutics captured in this report. It is worth mentioning that the analysis described in this section is based on a proprietary scoring criterion, which was informed via our company health indexing.
Section II Analysis of Investments
Chapter 10 offers insights from a detailed analysis of the funding and investment activity in this domain, since 2011. It includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies discussed in the report.
Section III Financial Analysis and Assessment of Business Risks
Chapter 11 is modelled in the likeness of an equity research report. It features a review of the overall digital therapeutics market from a financial perspective and includes detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of nine of the publicly listed companies within the innovator landscape dataset.
Chapter 12 includes detailed profiles of the public ventures engaged in the development of digital therapeutics. Each profile features a brief overview of the company, its insight from balance sheet (if available), details on its management team, a section on recent developments and key financial details (including company investment highlights, company fundamental and company technical analysis)
Chapter 13 includes a business risk analysis, offering insights encompassing several known categories of risk; these include operations-related risks, business-related risks, product / technology risks, financial / asset-related risks, and other risks.
Section IV Market Forecast and Opportunity Analysis
Chapter 14 features an insightful market forecast analysis, highlighting the estimated current and future size of the overall digital therapeutics market, till the year 2035. The opportunity has been segregated on the basis of type of solution (standalone software application, combination offerings of software application + device, combination offerings of software application + AI support , combination offerings of software application + personal coach, combination offerings of software application + device + AI support , combination offerings of software application + device + personal coach and others), type of therapy (curative solutions and preventive solutions), therapeutic area (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders and others) and geographical regions (North America, Europe, Asia-Pacific and Rest of the World.
Section V Analysis of Returns on Investment and Key Acquisition Targets
Chapter 15 includes case studies of instances where investors have exited various digital therapeutics-related ventures, offering insights on return on investments made (based on availability of data). The abovementioned estimates / details, offer a perspective on how past investments have paid off for investors as companies gradually went public, over time.
Chapter 16 offers insights from a proprietary analysis that leverages inputs from the startup health indexing and value proposition analysis (described in Section I), to offer qualitative recommendations on companies that are likely to be perceived as key acquisition targets.
Chapter 17 provides a pictorial summary of the overall project.
Chapter 18 is a set of appendices.
Table of Contents
EXCEL DELIVERABLE
1. INNOVATORS AND PRODUCTS DATASET
1.1. Analysis Notes
1.2. Innovator Landscape
1.3. Product Landscape
1.4. Value Proposition
1.5. Key Acquisition Targets
1.6. AI - AVII Appendices
2. FUNDING AND INVESTMENT ANALYSIS
2.1. Analysis Notes
2.2. Summary Dashboard
2.3. Capital Investments in Digital Therapeutics
2.4 AI - AIV Appendices
3. FUNDAMENTAL AND TECHNICAL FINANCIAL ANALYSIS
The information presented in this analysis is spread across separate MS Excel sheets, which provide information on key financial parameters and competitive insights based on historical and prevalent trends.
4. BUSINESS RISK ANALYSIS
4.1. Analysis Notes
4.2. Business Risk Data
4.3. AI - AVII Appendices
5. MARKET FORECAST AND OPPORTUNITY ANALYSIS
5.1. Analysis Notes
5.2. Market Forecast and Opportunity Analysis: Summary
5.3. Market Forecast and Opportunity Analysis: Base Scenario
5.4. Market Forecast and Opportunity Analysis: Conservative Scenario
5.5. Market Forecast and Opportunity Analysis: Optimistic Scenario
6. RETURN ON INVESTMENT
6.1. Analysis Notes
6.2. Estimated RoI for Investors in Company A
6.3. Estimated RoI for Investors in Company B
6.4. Estimated RoI for Investors in Company C
POWERPOINT DELIVERABLE
1. CONTEXT
2. PROJECT APPROACH
3. PROJECT OBJECTIVES
4. EXECUTIVE SUMMARY
Section I: Need for Digital Therapeutics and Innovators Landscape
5. THE DIGITAL THERAPEUTICS MARKET
5.1. Overview
5.2. Historical Milestones
5.3. Key Types of Solutions
5.4. Key Strategic Initiatives
5.5. Key Concepts, Marketed Products and Challenges
6. DIGITAL THERAPEUTICS: INNOVATOR LANDSCAPE
6.1. Methodology
6.2. Innovators in the Digital Therapeutics Market
6.3. Analysis of Competitive Landscape
6.4. Conclusion
7. DIGITAL THERAPEUTICS: PRODUCT LANDSCAPE AND COMPANY HEALTH INDEXING
7.1. List of Digital Therapeutics
7.2. Analysis of Product Landscape
7.3. Health Indexing Methodology
7.4. Company Health Indexing
8. VALUE PROPOSITION ANALYSIS
8.1. Overview and Methodology
8.2. Outreach-related Value
8.3. Developer Value
8.4. Product-related Value
8.5. Value to Patients
8.6. Concluding Remarks
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Overview and Methodology
9.2. Company Competitiveness Analysis
Section II Analysis of Investments
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Overview
10.2. Analysis by Type of Funding
10.3. Analysis by Geography and Most Active Players
10.4. Analysis of Trends Across Various Funding Categories
10.5. Summary of Funding and Investments
Section III Financial Analysis and Assessment of Business Risks
11. FINANCIAL ANALYSIS OF PUBLIC VENTURES
11.1. Fundamental Financial Analysis Overview
11.2. Financial Ratios (Interpretation Guide)
11.3. Case Study 1
11.4. Technical Financial Analysis Overview
11.5. Technical Indicators (Interpretation Guide)
11.6. Case Study 2
12. COMPANY PROFILES OF PUBLIC VENTURES
12.1 Akili Interactive
12.1.1. Key Highlights
12.1.1.1. Company Details
12.1.1.1. Company Overview
12.1.1.3. Insights from Balance Sheet
12.1.1.4. Management Team
12.1.1.5. Recent Developments
12.1.2. Key Financial Details
12.1.2.1. Company Investments
12.1.2.2. Company Fundamentals
12.1.2.3. Company Technicals
12.2. Better Therapeutics
12.2.1. Key Highlights
12.2.1.1. Company Details
12.2.1.1. Company Overview
12.2.1.3. Insights from Balance Sheet
12.2.1.4. Management Team
12.2.1.5. Recent Developments
12.2.2 Key Financial Details
12.2.2.1. Company Investments
12.2.2.2. Company Fundamentals
12.2.2.3. Company Technicals
12.3. Brain+
12.3.1. Key Highlights
12.3.1.1. Company Details
12.3.1.1. Company Overview
12.3.1.3. Insights from Balance Sheet
12.3.1.4. Management Team
12.3.1.5. Recent Developments
12.3.2. Key Financial Details
12.3.2.1. Company Investments
12.3.2.2. Company Fundamentals
12.3.2.3. Company Technicals
12.4. Dario Health
12.4.1. Key Highlights
12.4.1.1. Company Details
12.4.1.1. Company Overview
12.4.1.3. Insights from Balance Sheet
12.4.1.4. Management Team
12.4.1.5. Recent Developments
12.4.2 Key Financial Details
12.4.2.1. Company Investments
12.4.2.2. Company Fundamentals
12.4.2.3. Company Technicals
12.5. Ehave
12.5.1. Key Highlights
12.5.1.1. Company Details
12.5.1.1. Company Overview
12.5.1.3. Insights from Balance Sheet
12.5.1.4. Management Team
12.5.1.5. Recent Developments
12.5.2. Key Financial Details
12.5.2.1. Company Investments
12.5.2.2. Company Fundamentals
12.5.2.3. Company Technicals
12.6. Mindcure
12.6.1. Key Highlights
12.6.1.1. Company Details
12.6.1.1. Company Overview
12.6.1.3. Insights from Balance Sheet
12.6.1.4. Management Team
12.6.1.5. Recent Developments
12.6.2. Key Financial Details
12.6.2.1. Company Investments
12.6.2.2. Company Fundamentals
12.6.2.3. Company Technicals
12.7. Newtopia
12.7.1. Key Highlights
12.7.1.1. Company Details
12.7.1.1. Company Overview
12.7.1.3. Insights from Balance Sheet
12.7.1.4. Management Team
12.7.1.5. Recent Developments
12.7.2. Key Financial Details
12.7.2.1. Company Investments
12.7.2.2. Company Fundamentals
12.7.2.3. Company Technicals
12.8. Pear Therapeutics
12.8.1. Key Highlights
12.8.1.1. Company Details
12.8.1.1. Company Overview
12.8.1.3. Insights from Balance Sheet
12.8.1.4. Management Team
12.8.1.5. Recent Developments
12.8.2. Key Financial Details
12.8.2.1. Company Investments
12.8.2.2. Company Fundamentals
12.8.2.3. Company Technicals
12.9. Sharecare
12.9.1. Key Highlights
12.9.1.1. Company Details
12.9.1.1. Company Overview
12.9.1.3. Insights from Balance Sheet
12.9.1.4. Management Team
12.9.1.5. Recent Developments
12.9.2 Key Financial Details
12.9.2.1. Company Investments
12.9.2.2. Company Fundamentals
12.9.2.3. Company Technicals
13. BUSINESS RISK ANALYSIS
13.1. Overview and Methodology
13.2. Operations-related Risks
13.3. Business-related Risks
13.4. Financial / Asset-related Risks
13.5. Product / Technology Risks
13.6. Other Risks
13.7. Business Risk Summary
Section IV Market Forecast and Opportunity Analysis
14. MARKET FORECAST
14.1. Overview and Methodology
14.2. Global Digital Therapeutics Market, 2023-2035
14.3. Distribution Across Key Market Segments
14.3.1. Digital Therapeutics Market: Distribution by Type of Solution, 2023 and 2035
14.3.1.1. Digital Therapeutics Market for Standalone Software Application, 2023-2035
14.3.1.2. Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2023-2035
14.3.1.3. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2023-2035
14.3.1.4. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2023-2035
14.3.1.5. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2023-2035
14.3.1.6. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2023-2035
14.3.1.7. Digital Therapeutics Market for Other Types of Solutions, 2023-2035
14.3.2. Digital Therapeutics Market: Distribution by Type of Therapy, 2023 and 2035
14.3.2.1. Digital Therapeutics Market for Curative Therapy, 2023-2035
14.3.2.2. Digital Therapeutics Market for Preventive Therapy, 2023-2035
14.3.3. Digital Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035
14.3.3.1. Digital Therapeutics Market for Cardiovascular Disorders, 2023-2035
14.3.3.2. Digital Therapeutics Market for Chronic Pain, 2023-2035
14.3.3.3 Digital Therapeutics Market for Mental Health Problems, 2023-2035
14.3.3.4 Digital Therapeutics Market for Metabolic Disorders, 2023-2035
14.3.3.5 Digital Therapeutics Market for Neurological Disorders, 2023-2035
14.3.3.6 Digital Therapeutics Market for Respiratory Disorders, 2023-2035
14.3.3.7 Digital Therapeutics Market for Sleep Disorders, 2023-2035
14.3.3.8 Digital Therapeutics Market for Substance Use Disorders, 2023-2035
14.3.3.9 Digital Therapeutics Market for Other Disorders, 2023-2035
14.3.4. Digital Therapeutics Market: Distribution by Geographical Regions, 2023 and 2035
14.3.4.1. Digital Therapeutics Market in North America, 2023-2035
14.3.4.2. Digital Therapeutics Market in Europe, 2023-2035
14.3.4.3. Digital Therapeutics Market in Asia-Pacific and Rest of the World, 2023-2035
Section V Analysis of Returns on Investment and Key Acquisition Targets
15. ANALYSIS OF RETURNS ON INVESTMENT
15.1. Overview and Methodology
15.2. Case Studies
16. KEY ACQUISITION TARGETS
16.1. Overview
16.2. List of Key Acquisition Targets
17. CONCLUSION
18. APPENDICES
List Of Figures
Figure 5.1. Digital Therapeutics: Key Definitions and Background
Figure 5.2. Digital Therapeutics: Key Historical Milestones
Figure 5.3. Digital Therapeutics: Types of Solutions and Key Industry Players
Figure 5.4. Digital Therapeutics: Key Strategic Initiatives
Figure 5.5 Digital Therapeutics: Key Marketed Products and Challenges
Figure 6.1. Innovator Landscape: Distribution by Year of Establishment
Figure 6.2. Innovator Landscape: Distribution by Type of Venture
Figure 6.3. Innovator Landscape: Distribution by Company Size
Figure 6.4. Innovator Landscape: Distribution by Geography
Figure 7.1. Product Landscape: Distribution of Innovators by Number of Products
Figure 7.2. Product Landscape: Distribution by Type of Therapy
Figure 7.3. Product Landscape: Distribution of Products by Status of Development
Figure 7.4. Product Landscape: Distribution of Products by Type of Solution
Figure 7.5. Product Landscape: Distribution of Innovators by Therapeutic Area
Figure 8.1. Companies Offering Outreach-Related Value: Analysis of Companies Offering Very High Value
Figure 8.2. Companies Offering Developer Value: Analysis of Companies Offering Very High Value (2007-2013)
Figure 8.2. Companies Offering Developer Value: Analysis of Companies Offering Very High Value (2014 Onwards)
Figure 8.3. Companies Offering Product-related Value: Analysis of Companies Offering Very High Value
Figure 8.4. Companies Offering Value to Patients: Analysis of Companies Offering Very High Value
Figure 9.1. Competitiveness Analysis: Large Companies based in North America (Peer Group I)
Figure 9.2. Competitiveness Analysis: Mid-sized Companies based in North America (Peer Group II)
Figure 9.3. Competitiveness Analysis: Small Companies based in North America (Peer Group III)
Figure 9.4. Competitiveness Analysis: Very Small Companies based in North America (Peer Group IV)
Figure 9.5. Competitiveness Analysis: Large and Mid-sized Companies based in Europe (Peer Group V)
Figure 9.6. Competitiveness Analysis: Small Companies based in Europe (Peer Group VI)
Figure 9.7. Competitiveness Analysis: Very Small Companies based in Europe (Peer Group VII)
Figure 9.8. Competitiveness Analysis: Mid-sized Companies based in Asia-Pacific and Rest of the World (Peer Group VIII)
Figure 9.9. Competitiveness Analysis: Small and Very Small Companies based in Asia-Pacific and Rest of the World (Peer Group IX)
Figure 9.10. Competitiveness Analysis: Small and Very Small Companies based in Asia-Pacific and Rest of the World (Peer Group X)
Figure 10.1. Funding and Investment Analysis: Year-wise Distribution of Funding Instances and Amount Invested (2011-2022)
Figure 10.2. Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.3. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding
Figure 10.4. Funding and Investment Analysis: Geographical Distribution
Figure 10.5. Funding and Investment Analysis: Most Active Players (Number of Instances)
Figure 10.6. Funding and Investment Analysis: Most Active Players (By Amount Raised)
Figure 10.7. Awards / Grants: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.8. Awards / Grants: Geographical Distribution by Amount Invested
Figure 10.9. Awards / Grants: Most Active Investors
Figure 10.10. Seed Funding: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.11. Seed Funding: Geographical Distribution by Amount Invested
Figure 10.12. Seed Funding: Most Active Investors
Figure 10.13. Private Placements: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.14. Private Placements: Geographical Distribution by Amount Invested
Figure 10.15. Private Placements: Most Active Investors
Figure 10.16. Debt Financing: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.17. Debt Financing: Geographical Distribution by Amount Invested
Figure 10.18. Debt Financing: Most Active Investors
Figure 10.19. Venture (Series A): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.20. Venture (Series A): Geographical Distribution by Amount Invested
Figure 10.21. Venture (Series A): Most Active Investors
Figure 10.22. Venture (Series B): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.23. Venture (Series B): Geographical Distribution by Amount Invested
Figure 10.24. Venture (Series B): Most Active Investors
Figure 10.25. Venture (Series C): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.26. Venture (Series C): Geographical Distribution by Amount Invested
Figure 10.27. Venture (Series C): Most Active Investors
Figure 10.28. Venture (Series D): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.29. Venture (Series D): Geographical Distribution by Amount Invested
Figure 10.30. Venture (Series D): Most Active Investors
Figure 10.31. Venture (Series E, F, G and Unknown): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.32. Venture (Series E, F, G and Unknown): Geographical Distribution by Amount Invested
Figure 10.33. Venture (Series E, F, G and Unknown): Most Active Investors
Figure 10.34. Public Offering: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.35. Public Offering: Geographical Distribution by Amount Invested
Figure 10.36. Public Offering: Most Active Investors
Figure 10.36. Capital Investments in Digital Therapeutics Company: Summary of Funding and Investments , 2011-2022
Figure 11.1. Fundamental Financial Analysis: Annual Revenues and Key Balance Sheet Parameter-related Trends
Figure 11.2. Fundamental Financial Analysis: Liquidity Ratios
Figure 11.3. Fundamental Financial Analysis: Financial & Business Risk Ratios and Turnover / Efficiency Ratios
Figure 11.4. Fundamental Financial Analysis: Profitability Ratios
Figure 11.5. Fundamental Financial Analysis: Market Value Ratios & Stability Ratios
Figure 11.6. Technical Financial Analysis: Stock Price (Candlestick Chart) and Volume Traded
Figure 11.7. Technical Financial Analysis: 5-Day Moving Average
Figure 11.8. Technical Financial Analysis: 10-Day Moving Average
Figure 11.9. Technical Financial Analysis: 50-Day Moving Average
Figure 11.10. Technical Financial Analysis: Bollinger Band®
Figure 11.11. Technical Financial Analysis: Relative Strength Index
Figure 11.12. Technical Financial Analysis: Commodity Channel Index
Figure 11.13. Technical Financial Analysis: MACD
Figure 11.14. Technical Financial Analysis: Williams’ R Analysis
Figure 11.15. Technical Financial Analysis: Average Directional Index (ADX)
Figure 12.1. Akili Interactive: Company Fundamentals
Figure 12.2. Akili Interactive: Trend of Stock Prices Since Initial Public Offering
Figure 12.3. Better Therapeutics: Company Fundamentals
Figure 12.4. Better Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 12.5. Brain+: Company Fundamentals
Figure 12.6. Brain+: Trend of Stock Prices Since Initial Public Offering
Figure 12.7. Dario Health: Company Fundamentals
Figure 12.8. Dario Health: Trend of Stock Prices Since Initial Public Offering
Figure 12.9. Ehave: Company Fundamentals
Figure 12.10. Ehave: Trend of Stock Prices Since Initial Public Offering
Figure 12.11. Mindcure: Company Fundamentals
Figure 12.12. Mindcure: Trend of Stock Prices Since Initial Public Offering
Figure 12.13. Newtopia: Company Fundamentals
Figure 12.14. Newtopia: Trend of Stock Prices Since Initial Public Offering
Figure 12.15. Pear Therapeutics: Company Fundamentals
Figure 12.16. Pear Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 12.15. Sharecare: Company Fundamentals
Figure 12.16. Sharecare: Trend of Stock Prices Since Initial Public Offering
Figure 13.1. Business Risk Analysis: Operations-related Risks
Figure 13.2. Business Risk Analysis: Business-related Risks
Figure 13.3. Business Risk Analysis: Financial / Asset-related Risks
Figure 13.4. Business Risk Analysis: Product / Technology Risks
Figure 13.5. Business Risk Analysis: Other Risks
Figure 13.6. Summary of Business Risk Analysis
Figure 14.1. Digital Therapeutics Market: Forecast, 2023-2035 (USD Million)
Figure 14.2. Digital Therapeutics Market: Distribution by Type of Solution, 2023 and 2035
Figure 14.3. Digital Therapeutics Market for Standalone Software Applications, 2023-2035 (USD Million)
Figure 14.4. Digital Therapeutics Market for Combination Offerings (Standalone Software Applications + Device), 2023-2035 (USD Million)
Figure 14.5. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2023-2035 (USD Million)
Figure 14.6. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2023-2035 (USD Million)
Figure 14.7. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2023-2035 (USD Million)
Figure 14.8. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2023-2035 (USD Million)
Figure 14.9. Digital Therapeutics Market for Other Types of Solutions, 2023-2035 (USD Million)
Figure 14.10. Digital Therapeutics Market: Distribution by Type of Therapy, 2023 and 2035
Figure 14.11 Digital Therapeutics Market for Curative Solutions, 2023-2035 (USD Million)
Figure 14.12 Digital Therapeutics Market for Preventive Solutions, 2023-2035 (USD Million)
Figure 14.13 Digital Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035
Figure 14.14 Digital Therapeutics Market for Cardiovascular Disorders, 2023-2035 (USD Million)
Figure 14.15 Digital Therapeutics Market for Pain Management, 2023-2035 (USD Million)
Figure 14.16 Digital Therapeutics Market for Mental Health Problems, 2023-2035 (USD Million)
Figure 14.17 Digital Therapeutics Market for Metabolic Disorders, 2023-2035 (USD Million)
Figure 14.18 Digital Therapeutics Market for Neurological Disorders, 2023-2035 (USD Million)
Figure 14.19 Digital Therapeutics Market for Respiratory Disorders, 2023-2035 (USD Million)
Figure 14.20 Digital Therapeutics Market for Sleep Disorders, 2023-2035 (USD Million)
Figure 14.21 Digital Therapeutics Market for Substance Use Disorders, 2023-2035 (USD Million)
Figure 14.22 Digital Therapeutics Market for Other Disorders, 2023-2035 (USD Million)
Figure 14.23 Digital Therapeutics Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 14.24 Digital Therapeutics Market in North America, 2023-2035 (USD Million)
Figure 14.25 Digital Therapeutics Market in Europe, 2023-2035 (USD Million)
Figure 14.26 Digital Therapeutics Market in Asia-Pacific and Rest of the World, 2023-2035 (USD Million)
Figure 16.1. Key Acquisition Targets: Comparison of Scores with Overall Dataset
Figure 16.2. Key Acquisition Targets: Comparison based on Qualifying Parameters (1/4)
Figure 16.3. Key Acquisition Targets: Comparison based on Qualifying Parameters (2/4)
Figure 16.4. Key Acquisition Targets: Comparison based on Qualifying Parameters (3/4)
Figure 16.5. Key Acquisition Targets: Comparison based on Qualifying Parameters (4/4)
Figure 17.1. Concluding Landscape: North America
Figure 17.2. Concluding Landscape: Europe
Figure 17.3. Concluding Landscape: Asia-Pacific and Rest of the World
List Of Tables
Table 6.1. Key Innovators in the Digital Therapeutics Market
Table 7.1. Products Offered by Innovators in the Digital Therapeutics Market
Table 7.2. Company Health Indexing (1/15)
Table 7.3. Company Health Indexing (2/15)
Table 7.4. Company Health Indexing (3/15)
Table 7.5. Company Health Indexing (4/15)
Table 7.6. Company Health Indexing (5/15)
Table 7.7. Company Health Indexing (6/15)
Table 7.8. Company Health Indexing (7/15)
Table 7.9. Company Health Indexing (8/15)
Table 7.10. Company Health Indexing (9/15)
Table 7.11. Company Health Indexing (10/15)
Table 7.12. Company Health Indexing (11/15)
Table 7.13. Company Health Indexing (12/15)
Table 7.14. Company Health Indexing (13/15)
Table 7.15. Company Health Indexing (14/15)
Table 7.16. Company Health Indexing (15/15)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 11.2 Capital
- 2breathe Technologies
- 2Morrow
- 3L
- 3M Ventures
- 3VC
- 4point0 Health Ventures
- 500 Startups
- 5AM Ventures
- 7wire Ventures
- 9 Unicorns
- A-Round Capital
- A195 Capital
- Ababax Health
- Accel
- Accelmed
- Act Venture Capital
- Advance Venture Partners
- Advantage Capital
- AET Fund
- Aflac
- AI Fund
- AIB Seed Capital Fund
- aidhere
- Autisms Impact Fund
- Akili Interactive
- Akilia Partners
- Albion Capital
- AlbionVC
- Alex therapeutics
- Alfvén & Didrikson
- Alkeon Capital Management
- Allen & Company
- Alliance Global Partners (A.G.P.)
- Ally Bridge Group
- Alsace Business Angels
- Alumni Ventures
- Amalgam
- Amara Therapeutics
- Amazon Smbhav Venture Fund
- AME Cloud Partners
- AME Cloud Ventures
- Amelia
- American Investment Holdings
- Amgen Ventures
- Amiko Digital Health
- aMoon
- Ampersand Health
- Amplify Capital
- Ancora
- Andreessen Horowitz
- Anorak Ventures
- Anthemis
- Aphelion Capital
- AppliedVR
- Aptar Pharma
- Arboretum Ventures
- Ardea Capital Partners
- ArrowMark Partners
- Asabys Partners
- Asahi Kasei
- Aspect Ventures
- Atlantic Labs
- Atomico
- ATX Therapeutics
- Aviva Ventures
- AXA Venture Partners (AVP)
- Axil Capital
- B Capital
- Baillie Gifford
- Balderton Capital
- Baseline Ventures
- Bayer
- Beats Medical
- BeCareLink
- BEENEXT
- BehaVr
- Beneufit
- Bertelsmann Investments
- Bessemer Venture Partners
- Better Therapeutics
- Beyond Next Ventures
- Big Health
- Bimark
- Biofourmis
- BioTrak Therapeutics
- BIXINK
- Blackbird Ventures
- BlackRock
- Blackstone
- BlissDTx
- Bloom Burton
- Blue Cross Blue Shield of Massachusetts
- Blue Cross Blue Shield Venture Partners
- Blue Mesa Health
- Blue Note therapeutics
- Blue Venture Funds
- Blue Water Life Science Fund
- Blueprint Health
- BlueRun Ventures
- Boehringer Ingelheim
- Boehringer Ingelheim Venture Fund
- Bold Capital Partners
- Bold Health
- Bonit Capital
- Bose Ventures
- Bpifrance
- Brain Power
- Brain+
- Brandenburg Capital
- Bridge Bank
- Bridge Builders Collaborative
- Brooklands Capital Strategies
- Business Finland
- Cabin VC
- Caffeinated Capital
- Caixa Capital Risc
- Canaan Partners
- Canepa Advanced Healthcare Fund
- Canaan
- Canvas
- Canvas Ventures
- Medvest
- Cara.Care
- CardioRenal
- CAREvolution
- Carlyle
- Carrot Health
- Castle Peak (Acquired by CLP Holdings)
- Cedars-Sinai
- Centene
- CG Ventures
- CheckUp & Choices
- Chibagin Capital
- Cigna
- Cigna Ventures
- Cipla
- City Light Capital
- Civilization Ventures
- Click Therapeutics
- CLSA
- Coatue Management
- Cognoa
- COLOPL VR Fund
- Community Health Network of Connecticut
- Company K Partners
- Concord Health Partners
- Constant Therapy Health
- Correlation Ventures
- Cowen Private Investments
- CRCM Ventures
- Creandum
- Creas
- Creative Destruction Lab
- CrimsoNox Capital
- Crista Galli Ventures
- CureApp
- Curio
- Currae Healthtech
- CVS Health
- Cyberdine
- Dai-ichi Life
- DarioHealth
- dayzz
- Deerfield
- Deerfield Management Company
- Dendera Ventures
- Department of Defense
- Dexium Technologies
- DFJ
- DG Ventures
- Digbi Health
- Digithera
- DigiTx Partners
- DN Capital
- Dnurse Technology
- Doha Tech Angels
- Dopavision
- Double Peak Group
- Dreamit Ventures
- dreem
- Driehaus Capital Management
- Droobi Health
- dThx - Digital Therapeutics
- Duopharma Biotech
- e&
- Echo Health Ventures
- Eco-Fusion
- EDBI
- Eden Strategy Institute
- Ehave
- Eight Roads Ventures
- Eisai
- EIT Health
- Eleven Two Capital
- Ellerca Health
- Embr Labs
- Emperra
- Endeavor Catalyst
- ENDRA Life Sciences
- Enterprise Ireland
- Entrée Capital
- Equity4Good
- Esther Dyson
- Eurazeo
- European Union
- Eurostars
- Evidity Health Capital
- Exosystems
- Expon Capital
- Exponential Ventures
- Farallon Capital Management
- Fearless Ventures
- Feel Therapeutics
- Felicis Ventures
- Fenbushi Capital
- FFF Bayern
- Fidelity Management and Research Company
- Fifty Years
- FinTLV Ventures
- Fireside Ventures
- FirstMark Capital
- Fitterfly
- Floreo
- Flying Health
- FMZ Ventures
- Forth Management
- Founders Fund
- Foundry
- F-Prime Capital
- Franklin Templeton
- Freespira
- Freestyle Capital
- Frontier Venture Capital
- Fruit Street
- Frumtak Ventures
- Fundalogy
- Future Perfect Ventures
- Gaingels
- Galen Partners
- gBETA Medtech
- GC VR Tracker Fund
- Gelt Venture Capital
- General Atlantic
- General Catalyst
- Genesis Ventures
- Georgian Partners
- Giant Leap
- Gilde Healthcare
- Ginger
- GingerBread Capital
- Global Brain
- Global Founders Capital
- GlobalYeast
- Glooko
- Golden Seeds
- Green Shield Canada
- GrowX Venture Management
- GSR Ventures
- GuideWell Mutual Holding Corporation
- gumi Cryptos Capital
- H.I.G. BioHealth Partners
- Hadean Ventures
- Happify Health
- Healios
- Health Catalyst Capital
- HealthCap
- Heartcore Capital
- Hedia
- Hello Heart
- HelloBetter
- Hercules Capital
- Heritas Capital
- Heuristic Capital Partners
- Hevella Capital
- H ighmark Interactive
- High-Tech Gründerfonds
- Hikma Ventures
- Hinduja Group
- Hinge Health
- Holmusk
- Hyde Park Angels
- I Mercury Capital
- IBB Beteiligungsgesellschaft
- Idinvest
- iFeel Labs
- impute
- Incos Invest
- Industry Ventures
- i-nest capital
- INFOR Financial
- InHealth Ventures
- inMotion VR
- Innovate UK
- Innovation Works
- Insight Partners
- Insulet
- InsurTech.vc
- Integra Partners
- Intel Capital
- Intermountain Healthcare
- International Capital & Management Company (ICMC)
- Invest Detroit
- Investec
- Investitionsbank des Landes Brandenburg (ILB)
- ION Crossover Partners
- iSeed Ventures
- IT-Farm
- ITOCHU
- ITOCHU Technology Ventures (ITV)
- IVP
- Iwagin Business Creation Capital
- Iwagin Jigyo Souzou Capital
- J.P. Morgan
- JamJar Investments
- Janssen Research & Development
- Japan Impact Investment II
- JAZZ Venture Partners
- Jeff Weiner
- Jianke
- JOGO Health
- Johnson & Johnson Innovation
- Joint Academy
- Jolly Good
- Joy Ventures
- Joyable
- Joyance Partners
- K2 HealthVentures
- K2 Investment Partners
- Kaia Health
- Kaiser Permanente Ventures
- Kakao Ventures
- Kapor Capital
- Karista
- Karuna Labs
- Keio Innovation Initiative
- Kelvi
- Kenetic Advisors
- Kentucky Science and Technology Corporation (KSTC)
- Khosla Ventures
- Kicker Ventures
- Kiio
- Kima Ventures
- King River Capital
- Kinnevik
- KLAVA Innovation
- Kleiner Perkins
- Kleiner Perkins Caufield & Byers
- Koa Health
- KORE Digital Health Therapeutics
- Korea Investment Partners
- Korea Technology Finance
- Kortex Ventures
- Koshidaka
- Kranus Health
- KTB Network
- Kurbo Health
- Kwit
- Ladera Venture Partners
- Laguna Investment
- Laia Contigo
- Laidir Foundation
- Lark Health
- LaunchPad Venture Group
- Lead Edge Capital
- LEAP Axlr8r
- Leaps by Bayer
- Learn Capital
- Leksell Social Ventures (LSV)
- Lief Therapeutics
- LifeForce Capital
- Lifeline Ventures
- Lightspeed Venture Partners
- Limbix
- Limedix
- LionBirds
- Liquid 2 Ventures
- Livongo Health
- LongHash Ventures
- LRVHealth
- LUCID
- Lund University
- Lux Capital
- M Ventures
- M3 Ventures
- Magellan Health
- Magnetic Ventures
- Mahana Therapeutics
- MAIF Avenir
- Maine Technology Institute (MTI)
- Mana Ventures
- Manipal Education and Medical Group
- Manufacturers Life Insurance (Manulife)
- Massachusetts Life Sciences Center
- MassChallenge
- MassMutual Ventures
- Maven Ventures
- Maverick Ventures
- Mawendo
- Mayo Clinic
- McKesson Ventures
- MedRhythms
- Medtronic
- Melon Health
- mementor (Acquired by ResMed)
- Memorial Sloan Kettering Cancer Center
- MemorialCare Innovation Fund (MCIF)
- Merck Global Health Innovation Fund
- Merck Ventures
- Meru Health
- metaMe
- Metrodora Ventures
- Microsoft Ventures
- MiLA Capital
- MINDCURE
- Mindable Health
- MindBeacon Group
- MindMaze
- Mindset Health
- Mirae Asset Capital
- Mitsubishi UFJ Capital
- Mizuho Capital
- Mobio Technologies
- Molbio diagnostics
- Monashee Investment Management
- Montage Ventures
- Moonwhale Ventures
- Morningside Group
- Morningside Ventures
- moveUP
- MTIP
- Mundi Ventures
- Mundipharma
- My mhealth
- mynoise
- Naluri
- Nantahala Capital Management
- National Institute of Health
- National Institute of Mental Health
- National Institute on Aging
- National Science Foundation
- NCL Investment Management
- Neuberger Berman
- Neuroglee Therapeutics
- Neurotrack
- New Enterprise Associates
- New Leaf Venture Partners
- Newsenselab
- Newtopia
- NEXT Canada
- NextGen Venture Partners
- NGP Capital
- NightWare
- Nimble Ventures
- Nimbus Synergies
- Nina Capital
- Noaber
- Nokia Growth Partners
- Noom
- Nordic Brain Tech
- Nori Health
- Northwell Holdings
- Norwest Venture Partners
- Novartis
- Novartis Pharmaceuticals
- Novator Partners
- Novego
- Novo Holdings
- Novo Nordisk
- Nunaps
- Oak HC/FT
- Obvious Ventures
- Ocean Azul Partners
- Octopus Ventures
- Olive Tree Capital
- Omada Health
- Omega Capital
- Omidyar Technology Ventures
- OMRON Global
- One Drop
- ONE WORLD
- Openspace Ventures (formerly NSI Ventures)
- Optum Ventures
- OrbiMed
- OSF Ventures
- OurCrowd
- Oviva
- Ovulai
- Owl Ventures
- Ozential
- PaceZero Capital Partners
- Pacific Health Ventures
- Paretch
- Pathology Asia
- PayPal
- PBJ Capital
- Pear Therapeutics
- Pegasus Tech Ventures
- Peppermint VenturePartners
- Perceptive Advisors
- PFM Health Sciences
- Phenomenelle Angels
- Philips
- Phoenix Insurance
- Picus Capital
- PilotHouse
- Playground Global
- Plug and Play
- Polaris Partners
- Pond Capital
- Portland Seed Fund
- PrehApp
- PreSeedVentures
- Presence Capital
- Prodeko Ventures
- Propeller Health
- Prototron
- Providence Ventures
- Pura Vida Investments
- PureTech Health
- Quad
- Quadrille Capital
- Qure Ventures
- Rally Health
- Reaktor Ventures
- RediCare
- Redmile Group
- Rehappy
- Resolute Ventures
- Restore Health
- Rethink Impact
- Revelation Partners
- Revon Systems
- RHL Ventures
- RhythmiaBreath
- Ridgetop Health
- Roblox
- RRE Ventures
- Saama Technologies
- Safar Partners
- Safeguard Scientifics
- SAIF Partners
- Saisei Ventures
- Saison Ventures
- Salumedia
- Samsung Ventures
- Sanofi Ventures
- Sanofi-Genzyme BioVentures
- Sapien Ventures
- Sapphire Ventures
- Sarissa Capital Management
- Sarjan Health
- SBI Investment
- SBRI Healthcare
- Scale Capital
- Schoolhouse Partners
- ScientificMed
- SciFi VC
- Sectoral Asset Management
- SeedtoB Capital
- SelfBack
- Sequoia
- Sequoia Capital
- Seraph
- Serena Ventures
- SGInnovate
- Shanda Group
- Sharecare
- Shinsei Corporate Investment
- Shionogi
- Shoko Chukin Bank
- Sidekick Health
- Signia Venture Partners
- Silicon Valley Bank
- Silver Lake
- SilverCloud (Acquired by Anwell)
- Simplyhealth
- Sivan Innovation
- Skip Battle
- SMBC Venture Capital
- Social Capital
- Social Capital Suvretta Holdings
- Social Starts
- Sofina
- Soft Tech
- SoftBank Vision
- SoftBank Vision Fund
- Sompo Holdings
- Sonormed
- Sony Innovation Fund
- Sophia Bendz
- SOS Ventures
- Sozo Ventures
- SparkLabs
- Sparrow Ventures
- SpesNet
- Spice Capital
- SR One Capital Management
- Stanford Technology Ventures Program (STVP)
- Stanley Park Ventures
- Startmate
- Startupbootcamp Digital Health Berlin
- StartX
- Stateline Angels
- SternAegis Ventures
- STIFEL
- Storm Ventures
- Stress Point Health
- Sumitomo Mitsui Trust Holdings
- Summer VC
- Summit Partners
- SUSMED
- Sway Ventures
- Sweet Capital
- sweetch
- Swing Therapeutics
- Sympatient
- Symphony
- Tal Ventures
- Techstars
- Teladoc Health
- TELUS Ventures
- Temasek
- The Valley Fund
- The Venture Reality Fund
- The Vertical Group
- Think.Health
- Tiger Global
- Tokyo Century
- TomorrowVentures
- Toyoshima & Co
- Trend Forward Capital
- Trinity Capital
- Triumf Health
- Trustbridge
- TT Capital Partners
- Turnaround Health
- U.S. Venture Partners
- Ulster Bank Diageo Venture Fund (Investec Ventures)
- Unconventional Ventures
- UnityPoint Health Ventures
- UpLift Health
- Velmio
- Venrock
- Venture Catalysts
- Verve Capital Partners
- Verve Ventures
- Vida Health
- Vigo
- Virta Health
- Virtue Health
- Vitadio
- Vivid Vision
- ViViRA
- Wakestream Ventures
- Walking Ventures
- Wanxiang America Corporation
- Wayra
- WEA Trust
- Webb Investment Network
- Wellington Management Company
- Wellington Partners
- Wells Fargo Capital Finance
- Wellstreet
- Wellthy Therapeutics
- Werth Family Investment Associates
- Whale Rock Capital Management
- White Fund
- Wisconsin Investment Partners
- Wisdom
- Woebot Health
- Workday Ventures
- Workit Health
- WP Global Partners
- WRF Capital
- Y Combinator
- Zaffre Investments
- Zenworks
- ZINC
Methodology
LOADING...
